Key facts
- Thelior Bio’s last known valuation is $6.1M (Jul 2025).
- It has raised $2.7M; the latest was Seed Round ($2.7M) in Jul 2025.
- Notable investors include Oxford Science Enterprises.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Thelior Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Thelior Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Thelior Bio
Developer of targeted biologic treatments intended for the long-term management of inflammatory bowel conditions. The company's platform focuses on restoring gut lining integrity by using monoclonal molecules to block tissue-damaging signals identified through patient-derived molecular research, enabling individuals with Crohn's disease and ulcerative colitis who are unresponsive to current therapies to achieve sustained remission, reduced relapse frequency, and improved protection against complications such as scarring and fistulas.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2025
- Ownership
- Privately Held (backing)
Thelior Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Thelior Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Thelior Bio in its N-PORT filings yet. We sweep new filings monthly.